ACIU•benzinga•
AC Immune Reports Interim Results From Phase 2 Trial Of ACI-7104.056 Active Immunotherapy In Early Parkinson's Disease; Well Tolerated With No Clinically Relevant Safety Issues Reported, Says 100% Of Patients Responded Against The Target Antigen
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 14, 2024 by benzinga